GlassScriptPhysician profile
Cynthia Ann Eckert
NPI 1700882750
$3,824.07
in general payments reported to CMS, 2019-2025
34 companies · $825 in 2025
The $825 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $146 · 2021: $122 · 2022: $1,075 · 2023: $463 · 2024: $694 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $620.51 | 2022 | |
| Abbvie INC. | $418.26 | 2019-2023 | Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $375.97 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $363.47 | 2024-2025 | |
| Biogen, INC. | $362.56 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $217.20 | 2019-2023 | Injectafer |
| Myovant Sciences INC. | $215.99 | 2021-2022 | |
| Astellas Pharma US INC | $208.12 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $201.54 | 2021-2025 | |
| Pfizer INC. | $82.37 | 2022-2024 | |
| Organon LLC | $80.70 | 2024-2025 | Nexplanon |
| Myriad Women'S Health, INC. | $68.11 | 2023 | Myrisk |
| Therapeuticsmd, INC. | $65.11 | 2019-2022 | |
| Medtronic, INC. | $59.18 | 2022-2024 | Ligasure, Truclear |
| Millicent US INC | $55.82 | 2024-2025 | Femlyv, Femring, Intrarosa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $47.81 | 2019-2024 | Acessa Provu System |
| Covidien LP | $41.51 | 2019 | |
| Dexcom, INC. | $35.07 | 2025 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $30.31 | 2022 | |
| Allergan, INC. | $30.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.97 | 2023 | |
| Novo Nordisk INC | $21.67 | 2023 | Wegovy |
| Exeltis, USA INC. | $20.70 | 2025 | Slynd |
| Davol INC. | $20.46 | 2024 | Arista Ah Flexitip |
| Takeda Pharmaceuticals U.S.A., INC. | $19.50 | 2023 | |
| Mission Pharmacal Company | $19.39 | 2019 | |
| Pharmacosmos Therapeutics INC. | $19.16 | 2024 | Monoferric |
| Biohaven Pharmaceutical Holding Company LTD. | $17.79 | 2022 | |
| Lupin INC. | $14.84 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.65 | 2019 | |
| Minerva Surgical, INC | $13.47 | 2019 | |
| Boston Scientific Corporation | $13.13 | 2019 | |
| Merck Sharp & Dohme LLC | $12.33 | 2019 | |
| Radius Health, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Eckert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.